HM13

Across TCGA pan-cancer cohorts, HM13 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HM13 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher HM13 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated HM13 expression acts as an unfavorable survival marker, although some lineages such as HNSC and COAD show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where HM13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.767	0.506	<.001	61	view →
CCRCC	DFS	Tertile	III,IV	0.294	0.717	.002	19	view →
PDAC	DFS	Tertile	II,III,IV	0.333	0.569	.029	7	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
LUAD	OS	Tertile	All	1.000	0.853	.012	2	view →
GBM	DFS	Quartile	All	0.696	0.797	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HM13–HNSC (DFS)

Open the HNSC breakdown →